Brief: Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data
17/09/2025 14:02
Sept 17 (Reuters) - Palisade Bio Inc PALI.O: PALISADE BIO REPORTS POSITIVE PALI-2108 PHASE 1B CLINICAL DATA PALISADE BIO INC - PHASE 1B FSCD STUDY DOSING EXPECTED IN 2H 2025 PALISADE BIO INC - PHASE 2 IND SUBMISSIONS ANTICIPATED IN 1H 2026 PALISADE BIO INC - PALI-2108 DEMONSTRATED FAVORABLE SAFETY, WITH NO SERIOUS ADVERSE EVENTS, LAB ABNORMALITIES, OR EKG CONCERNS Source text: ID:nGNX9ySGjn Further company coverage: PALI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing